Crizotinib (PF-02341066)

For research use only. Not for use in humans.

Pfizer辉瑞授权 目录号:S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1812.55 现货
RMB 900.49 现货
RMB 1372.81 现货
RMB 4681.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Crizotinib (PF-02341066)发表文献255篇:

产品安全说明书

c-Met抑制剂选择性比较

生物活性

产品描述 Crizotinib (PF-02341066) 克唑替尼是一种有效的c-MetALK抑制剂,在细胞试验中IC50分别为11 nM 和 24 nM。它同时也是有效的ROS1抑制剂,其Ki值小于0.025 nM。Crizotinib可在多种肺癌细胞系中通过抑制STAT3通路来诱导自噬。
靶点
ROS1 [6]
(Cell-free assay)
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
<0.025 nM(Ki) 11 nM 24 nM
体外研究

PF-2341066作用于mIMCD3小鼠和MDCK犬上皮细胞,作用于c-Met磷酸化作用时具有相似效果,IC50分别为5 nM 和20 nM。PF-2341066作用于表达c-Met ATP-结合位点突变型V1092I 或H1094R或 P-环突变 M1250T 的NIH3T3 细胞,具有相似的活性,且活力增高,IC50分别为19 nM,2 nM 和15 nM,而作用于表达野生型受体的NIH3T3 细胞时,IC50为13 nM。[1] 相反, 观察到PF-2341066作用于表达c-Met活化环突变型Y1230C 和Y1235D的细胞时,与作用于野生型受体相比,效果发生显著改变,IC50分别为127 nM 和92 nM。PF-2341066 作用于分别表达内源性c-Met 突变体R988C和 T1010I 的NCI-H69 和HOP92 细胞,也有效抑制c-Met 磷酸化, IC50分别为13 nM 和16 nM。与作用于c-Met相比,PF-2341066作用于VEGFR2 和PDGFRβ RTKs, 选择性高1000多倍,作用于IRK和Lck选择性高250多倍,作用于Tie2, TrkA,和TrkB选择性高40到60倍。PF-2341066 作用于RON和 Axl RTKs时选择性为20到30倍。相反,PF-2341066 作用于表达ALK RTK 的核磷蛋白 (NPM)- 间变性淋巴瘤激酶(ALK) 致癌融合突变体和 KARPAS299人间变性大细胞淋巴瘤(ALCL)细胞系时具有相近的IC50值,为24 nM。PF-2341066抑制c-Met依赖的癌细胞的肿瘤表现型,和内皮细胞的血管生成表现型。PF-2341066抑制人GTL-16胃癌细胞生长,IC50为9.7 nM。PF-2341066诱导 GTL-16细胞凋亡,IC50 为8.4 nM。PF-2341066 抑制HGF刺激的人NCI-H441肺癌细胞迁移和入侵,IC50分别为11 nM 和6.1 nM。PF-2341066抑制 MDCK细胞散射,IC50为16 nM。PF-2341066 抑制HGF-刺激的c-Met磷酸化,细胞存活,和Matrigel入侵,IC50分别为11 nM, 14 nM和35 nM。此外, PF-2341066抑制纤维蛋白胶中的血清刺激的 HMVEC分支小管形成 (形成血管)。[1] PF-2341066 作用于Karpas299 或SU-DHL-1 ALCL细胞,也有效抑制 NPM-ALK磷酸化,IC50 为24 nM。PF-2341066 有效抑制细胞增殖,伴随着使细胞周期停在G(1)-S期,且诱导 ALK阳性的 ALCL 细胞凋亡,IC50为30 nM, 但是作用于ALK阴性的淋巴瘤细胞则无效果。 [2] 此外, PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长 (例如,增殖和存活)和转移 (例如,入侵和形成克隆)。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 NIH6dXVEgXSxdH;4bYMhSXO|YYm= NXTtb|dYPDhiaB?= NG\FfWlFVVOR MmS5R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKEGOSzDGNVE4PExibYX0ZY51KGOxZYjwdoV{e2mwZzDFUWw1KHerdHigTWM2OCCxZjCwMlYzKM7:TR?= M3WwfFIyPTd{NUi5
BAF3 M2PrcWN6fG:2b4jpZ{BCe3OjeR?= MYW0PEBp NGDOR4tFVVOR NW\aWGU{S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFHMT{BNOTF7Nl2gcZV1[W62IHPv[ZhxemW|c3nu[{BGVUx2IIfpeIghUUN3MDDv[kAzNjJizszN NFfqc4gzOTV5MkW4PS=>
BAF3 Mnz6R5l1d3SxeHnjJGF{e2G7 M{DFVVQ5KGh? M4LHfWROW09? NVf6eGF{S3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIFXNUFQuSUyNIIfpeIghUUN3MDDv[kAxNjJ6IN88US=> MV6yNVU4OjV6OR?=
Kelly MojVR5l1d3SxeHnjJGF{e2G7 MUTEUXNQ M4r2T2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN Ml7JNlE2PzJ3OEm=
SH-SY5Y MlHIR5l1d3SxeHnjJGF{e2G7 MmPYSG1UVw>? MXzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN MoHQNlE2PzJ3OEm=
SMS-KCN Mln4R5l1d3SxeHnjJGF{e2G7 M3LsZmROW09? Ml;BR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV21UNUuFTjDj[YxteyCneIDy[ZN{cW6pIFHMT{BTOTJ5NWGgcZV1[W62IIfpeIghUUN3MDDv[kAxNjlzIN88US=> Mn7FNlE2PzJ3OEm=
BAF3 M2XjNGN6fG:2b4jpZ{BCe3OjeR?= NV7Ue3VvPDhiaB?= NYPqXJFqTE2VTx?= Mk\oR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmFHOyClZXzsd{BmgHC{ZYPzbY5oKFSnbD3BUGshf2m2aDDJR|UxKG:oIECuNVkh|ryP NWfIeGVKOjF3N{K1PFk>
3T3 NYfEXFh4TnWwY4Tpc44hSXO|YYm= NWnzdHV4OSCq MYDEUXNQ NFnUT4FKdmirYnn0bY9vKG:oIGLPUkBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? MmWzNlE5OTJ2MUS=
3T3-E MmnQSpVv[3Srb36gRZN{[Xl? Mmm4NUBp NVG2OZVUTE2VTx?= NFPvSYZKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? MWCyNVgyOjRzNB?=
A549 NYXvfWRLU2mwYYPlJGF{e2G7 MYixJIg> MmTISG1UVw>? MV3Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KGNvTVXUJItqdmG|ZTDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDIS2YucW6mdXPl[EBifXSxcHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxQCEQvF2= NWXXToNMOjF6MUK0NVQ>
BAF3-BCL M13jV2Z2dmO2aX;uJGF{e2G7 NHPKSZMyKGh? NW[xd2I2TE2VTx?= NXWxU|hoUW6qaXLpeIlwdiCxZjDBRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEGuNVU6KM7:TR?= M3T5NlIyQDF{NEG0
HEK293 M1zWNmZ2dmO2aX;uJGF{e2G7 M2TCTFEhcA>? NVjXW|dYTE2VTx?= MlHSTY5pcWKrdHnvckBw\iCDWFygZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMkm0JO69VQ>? NID1UJgzOThzMkSxOC=>
HEK293 MnPHSpVv[3Srb36gRZN{[Xl? MWCxJIg> NUPsOXhITE2VTx?= NGjpc3ZKdmirYnn0bY9vKG:oIFnSJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iB{Lki4O{DPxE1? M4XXO|IyQDF{NEG0
Jurkat MkjxSpVv[3Srb36gRZN{[Xl? NV:wcFUyOSCq M3e3fmROW09? NV\MU5JJUW6qaXLpeIlwdiCxZjDMR2sh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIEKuO|QyKM7:TR?= M2L0fVIyQDF{NEG0
KARPAS299 MXzLbY5ie2ViQYPzZZk> NVLRRpBNOSCq NIfHflNFVVOR NUXFfHp6UW6qaXLpeIlwdiCxZjDBUGsh[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFIh|ryP M4PmdFIyQDF{NEG0
PAE NX7xbG9[TnWwY4Tpc44hSXO|YYm= NFHQb3kyKGh? Mm\MSG1UVw>? NEPSbm9KdmirYnn0bY9vKG:oIGTST2Ih[XO|ZYPz[YQh[XNiZ4Lve5RpKG[jY4Tvdk1qdmS3Y3XkJIF2fG:yaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuN|k6KM7:TR?= M{fhZVIyQDF{NEG0
BAF3 MlHFSpVv[3Srb36gRZN{[Xl? NWDCSoR7Oi1|IHS= MnPnSG1UVw>? NWXYNlFyUW6qaXLpeIlwdiCxZjDUSWwu\nW|ZXSgbY5{fWyrbjDy[YNmeHSxcjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDFwNkSzJO69VQ>? MXKyN|c1OjJ3Mh?=
KARPAS299 M3HNTmN6fG:2b4jpZ{BCe3OjeR?= MmG2Nk0{KGR? NEjOOG5FVVOR MUnJR|UxRTBwME[0NkDPxE1? NELoN4kzOzd2MkK1Ni=>
EBC1 NXnseW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NkBp MYTEUXNQ MmW0TWM2OD1yLkCyN{DPxE1? NHXCT4EzOzl7M{OyPC=>
HCT116 NG\vOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHxOmVKPzJiaB?= NVrPOpI2TE2VTx?= MlnBTWM2OD1zND64NkDPxE1? M1ewZVI{QTl|M{K4
MCF7 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHHO|IhcA>? NGnXeXVFVVOR MmezTWM2OD17LkW4JO69VQ>? MmnzNlM6QTN|Mki=
MDA-MB-231 NHPr[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD6[HlWPzJiaB?= NXnDUG9ZTE2VTx?= NXXZWJZwUUN3ME2xNE45KM7:TR?= M1vyXlI{QTl|M{K4
MKN45 M1vSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rGflczKGh? NHPVc2lFVVOR NWPEXZRyUUN3ME2wMlAyOyEQvF2= NGPXbWIzOzl7M{OyPC=>
NCI-H441 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfjfFlLPzJiaB?= Ml3jSG1UVw>? NUTE[3ZPUUN3ME2xO{4zPSEQvF2= M1fPZlI{QTl|M{K4
NCI-H661 NI\MSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrmcGV6PzJiaB?= NGqzclBFVVOR M4PwVWlEPTB;MUGuOFch|ryP NX\0NVV2OjN7OUOzNlg>
SK-MEL-28 NWTmZVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDwe444OiCq MnvMSG1UVw>? MXHJR|UxRTFyLkm3JO69VQ>? MViyN|k6OzN{OB?=
SKOV3 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH61TGo4OiCq NWmxUIo4TE2VTx?= M1:1W2lEPTB;MUKuPFUh|ryP NUjXTVBGOjN7OUOzNlg>
SNU5 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrKUnk4OiCq MlnKSG1UVw>? NHzIUIxKSzVyPUCuNFE3KM7:TR?= M3PSTVI{QTl|M{K4
NCI-H2228 NEHNSItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrw[m5tPzJiaB?= MXXEUXNQ NYTGXplRUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMUG4JO69VQ>? MnvpNlQ1OzJ7MEm=
NCI-H3122 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLGO|IhcA>? MX\EUXNQ M3vGd2lvcGmkaYTpc44hd2ZiQVzLMYZ2e2mxbjDkdol3\W5iY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjFyODFOwG0> MoDRNlQ1OzJ7MEm=
NCI-H3122 MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DRUVczKGh? NXLjNWd4TE2VTx?= MnTvTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugS|EzPjmDIH31eIFvfCC5aYToJGlEPTBib3[gNE43OjNizszN NEDmb3AzPDR|MkmwPS=>
NCI-H3122 NV;aUWpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUe3NkBp NXnDWVE3TE2VTx?= MmDYTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25iaX6gbJVu[W5iTlPJMWg{OTJ{IHPlcIx{KGijcnLvdolv\yCDTFugUFEyQT[PIH31eIFvfCC5aYToJGlEPTBib3[gNE45OzhizszN NVT5[mdIOjR2M{K5NFk>
NIH-3T3 M3G2cGtqdmG|ZTDBd5NigQ>? MX[xJIg> MmHrSG1UVw>? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJJdqdGRidInw[UBGVUx2LX\1d4VlKEGOSzDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc5J6dGG2ZXSgRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLkC4JO69VQ>? MmK3NlQ1OzJ7MEm=
NIH-3T3 NH7DW|NMcW6jc3WgRZN{[Xl? NIXhfngyKGh? NFfmW|dFVVOR MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFexNlY6SSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZyNTFOwG0> NViwe4J3OjR2M{K5NFk>
NIH-3T3 NH\WXINMcW6jc3WgRZN{[Xl? M1TDN|EhcA>? MmPtSG1UVw>? MYHJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIGOxNlA3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjZ{NjFOwG0> M4TGTlI1PDN{OUC5
NIH-3T3 MmTiT4lv[XOnIFHzd4F6 MmnmNUBp M3rJcmROW09? NF3CSGZKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJGwyOTl4TTDteZRidnRiZYjwdoV{e2WmIHHzd4V{e2WmIHHzJJBpd3OyaH:tRWxMKGyndnXsJJdqfGhiSVO1NEBw\iByLki0N{DPxE1? NHXVOXgzPDR|MkmwPS=>
NIH-3T3 NGSxbYlMcW6jc3WgRZN{[Xl? MXuxJIg> NVPzZYlUTE2VTx?= MmnTTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDMNVE2OlJibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOS5yMk[g{txO M4\TclI1PDN{OUC5
BAF3 M1ToVGZ2dmO2aX;uJGF{e2G7 MX23NkBp MWrEUXNQ M2G3U2lvcGmkaYTpc44hd2ZiTmDNM2FNUyC2cnHud4Zm[3SnZDDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cCCrbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjB3MTFOwG0> MojJNlQ1Pjh4M{K=
BAF3 MmnBR5l1d3SxeHnjJGF{e2G7 MYK3NkBp MlvDSG1UVw>? Ml\CTWM2OD1yLkm4JO69VQ>? NW\R[|BHOjR2Nki2N|I>
NIH-3T3 MWfLbY5ie2ViQYPzZZk> M2PU[FEhcA>? Mkm1TY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC5zNkWg{txO MkP4NlQ5OTlzMU[=
NIH-3T3 MlPtT4lv[XOnIFHzd4F6 MWKxJIg> M1j4VmlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugR|EyPT[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNEe4JO69VQ>? NXjscmd{OjR6MUmxNVY>
NIH-3T3 NIXPR4NMcW6jc3WgRZN{[Xl? NEDVPHkyKGh? NYSyVXpUUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh|ryP M{TWNFI1QDF7MUG2
NIH-3T3 M{Dm[WtqdmG|ZTDBd5NigQ>? MlLENUBp NFTPdnVKdmirYnn0bY9vKG:oIHj1cYFvKEWPTESt[pV{\WRiQVzLJFEyPTGWaX7zJI12fGGwdDDlfJBz\XO|ZXSgZZN{\XO|ZXSgZZMheGixc4Doc{1CVEtibHX2[Ywhf2m2aDDJR|UxKG:oIEOuNFM6KM7:TR?= NW\r[ox3OjR6MUmxNVY>
KARPAS299 NEfqSnJMcW6jc3WgRZN{[Xl? M4e3eVkxKG2rbh?= NUjNdph{TE2VTx?= MoS3TY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO MonoNlQ6ODB5NUC=
MKN 45 MWjLbY5ie2ViQYPzZZk> NYjicIk2OSCq Mn\wSG1UVw>? MUnJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> Mn;mNlQ6ODB5NUC=
A549 MVTDfZRwfG:6aXOgRZN{[Xl? NWj0[Yg{PDhiaB?= MUHEUXNQ NU\pdppVUUN3MDDv[kA1NjB6NDFOwG0> NEjtRYgzPDlyMEizNC=>
NCI-H1975 M3v5NmN6fG:2b4jpZ{BCe3OjeR?= NIfqRnM1QCCq Ml\2SG1UVw>? M1O4[WlEPTBib3[gO{42PTFizszN MXmyOFkxODh|MB?=
NCI-H1993 MYnDfZRwfG:6aXOgRZN{[Xl? MYC0PEBp MVLEUXNQ NIG5SWFKSzVyIH;mJFAvODZzIN88US=> MnWzNlQ6ODB6M{C=
NCI-H1993 NY\ac29HSXCxdH;zbZMhSXO|YYm= M1PITVEh|ryP NFzvPVIzPCCq NEfEb|FFVVOR M4PSS4Rw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= MoP1NlQ6ODB6M{C=
NIH-3T3 NUe1SpNKS3m2b4TvfIlkKEG|c3H5 NWTz[m84PDhiaB?= MV7EUXNQ NXnaOXRRUUN3MDDv[kAxNjN4NDFOwG0> M3K0TlI1QTByOEOw
EBC1 NYXRemVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0bXA4OiCq M1PSV2ROW09? MV7JR|UxKG:oIECuNFA3QSEQvF2= NWLhXm85OjR7MEC4N|E>
KARPAS299 NELsfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvTbpU4OiCq MU\EUXNQ MXfJR|UxKG:oIECuNkDPxE1? M4Cyc|I1QTByOEOx
NB1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK0copMUUN3ME25NU46QCCwTR?= MoHYV2FPT0WU
NCI-SNU-5 MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFyNT63OUBvVQ>? MV;TRW5ITVJ?
SR NWe5SJpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF{Nj6zNUBvVQ>? MUjTRW5ITVJ?
SF539 NXLrdJhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Xib2lEPTB;MkC0MlI1KG6P MlnQV2FPT0WU
SU-DHL-1 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSxTWM2OD1|M{[uPFIhdk1? NX3N[Ip3W0GQR1XS
SCC-3 MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjYRnBQUUN3ME2zOVYvPzZibl2= M1PqfHNCVkeHUh?=
DEL NYr1Zm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN4OT65JI5O NXfvZ5o5W0GQR1XS
CTV-1 MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLaTWM2OD13OU[uOFghdk1? NUjL[pRiW0GQR1XS
EM-2 M17zSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTNTFhIUUN3ME22NFEvOzRibl2= MmDxV2FPT0WU
MHH-CALL-2 M3TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPrNlVKSzVyPU[4Nk42PyCwTR?= NGrTXY1USU6JRWK=
KM12 NITm[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHJTWM2OD15ME[uPUBvVQ>? M362NnNCVkeHUh?=
KINGS-1 M4PFWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX0UGJKSzVyPUe0PU44PSCwTR?= M1nLS3NCVkeHUh?=
MEG-01 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq1OXNKSzVyPUi1O{43PiCwTR?= NWHBWHY1W0GQR1XS
BV-173 M{nBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrBWZlKSzVyPUGuNFU6QTdizszN NInidm9USU6JRWK=
LAMA-84 M4q0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HDNGlEPTB;MT6zPFI5OiEQvF2= MWrTRW5ITVJ?
KARPAS-299 NH61RoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;NRVhRUUN3ME2xMlQxQDZzIN88US=> Mo\RV2FPT0WU
K-562 NXL5RXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzmTWM2OD1zLkeyNlY6KM7:TR?= NXXzbZd1W0GQR1XS
SK-LMS-1 M2jqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnUV4ZOUUN3ME2xMlc3QDZ5IN88US=> MnzUV2FPT0WU
MOLT-16 NHvoW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwOUW1O|Uh|ryP MnXHV2FPT0WU
CMK NETwd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwOU[xOVkh|ryP NF3aVXlUSU6JRWK=
ST486 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfRenZKSzVyPUKuOFMxPzNizszN M1f2bnNCVkeHUh?=
CI-1 NXHKVmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITBRoVKSzVyPUKuOFk3PTlizszN NHW5eI1USU6JRWK=
KP-N-RT-BM-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG1S45KSzVyPUKuO|AyOjJizszN NYPpT|BiW0GQR1XS
ALL-PO NEDsR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTNwMUiyNFch|ryP NWXpXppqW0GQR1XS
KS-1 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTNwMkGyNlUh|ryP M4PR[nNCVkeHUh?=
Becker MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwMkO5N{DPxE1? M4HS[3NCVkeHUh?=
GDM-1 M3TtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnq4TWM2OD12LkK0OlE4KM7:TR?= MUfTRW5ITVJ?
BC-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe0TWM2OD12LkS5Nlc4KM7:TR?= NVPhbVExW0GQR1XS
NB14 NXT3VZY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;2b4RKSzVyPUSuPFM2OjRizszN MUXTRW5ITVJ?
NOS-1 M1rZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXXe5VKSzVyPUWuN|M5PzRizszN NWPC[JVmW0GQR1XS
MZ1-PC NEmwPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDPbmFKSzVyPUWuPFIyPTFizszN NVKyfGZYW0GQR1XS
A498 MlLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX25dVlMUUN3ME22MlA5PDd|IN88US=> NF6zVXpUSU6JRWK=
EW-16 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnDTWM2OD14LkO3O|c{KM7:TR?= MlLwV2FPT0WU
NALM-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD5fopKSzVyPU[uOlg{QDdizszN NWXqVmdpW0GQR1XS
EB-3 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXaTWM2OD15LkC3NlM{KM7:TR?= M2LtRnNCVkeHUh?=
697 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPiRotKSzVyPUmuNlQ{OjlizszN M2X6b3NCVkeHUh?=
Ramos-2G6-4C10 M3fRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTlwNUm4OFIh|ryP NXXKSVJ5W0GQR1XS
KNS-81-FD MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ex[GlEPTB;OT62PVY2OyEQvF2= NGr4[mlUSU6JRWK=
HUTU-80 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTyS5FrUUN3ME25Mlc1PjR{IN88US=> NEXKOVdUSU6JRWK=
LS-411N NVfyWo5qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHqW446UUN3ME2xNE4xPTZ5IN88US=> NUjJepE5W0GQR1XS
RPMI-8402 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnIS2pKSzVyPUGwMlEyPiEQvF2= NEXNV5JUSU6JRWK=
KU812 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnPZnpvUUN3ME2xNE4zQTlzIN88US=> M{fqXXNCVkeHUh?=
EW-1 NVr5[oZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;ZfVZKSzVyPUGwMlQ1OjVizszN NVXEco9uW0GQR1XS
HC-1 NF;mTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHFdlhNUUN3ME2xNE41QDR2IN88US=> MlnRV2FPT0WU
NB69 NEPDbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlOxTWM2OD1zMD61NFQ{KM7:TR?= M33aZnNCVkeHUh?=
MFH-ino NV\Kemh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULyVFZFUUN3ME2xNE45OzB|IN88US=> M2PhXXNCVkeHUh?=
CCRF-CEM NEfOZpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f3OmlEPTB;MUGuOVk4KM7:TR?= MmfyV2FPT0WU
SK-N-DZ NIDH[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUm1Zm52UUN3ME2xNk4xPDN4IN88US=> MV7TRW5ITVJ?
NCI-H720 NVPmbnRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HPT2lEPTB;MUKuNVcxPSEQvF2= MV\TRW5ITVJ?
HCC1187 NGmy[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TXbWlEPTB;MUKuNlA1OSEQvF2= Mm[2V2FPT0WU
IST-SL2 NVXkeoVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\iTJdqUUN3ME2xNk41QDd{IN88US=> NVzmboVQW0GQR1XS
KE-37 NHn4fYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jqbGlEPTB;MUKuO|k3PiEQvF2= NU\ac4NGW0GQR1XS
HCC1599 M1XTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTZTWM2OD1zMj65NFY6KM7:TR?= NIPSdZdUSU6JRWK=
A4-Fuk NX30dmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF{Lkm1PFYh|ryP M1TTc3NCVkeHUh?=
NKM-1 M{XJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnWSJBKSzVyPUGzMlI6OjVizszN NWjz[ZpIW0GQR1XS
BE-13 NVLwRWM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV25NJE1UUN3ME2xN{44QTh7IN88US=> NH3NTFdUSU6JRWK=
MV-4-11 MmPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTF2LkCzNlQh|ryP M4rORXNCVkeHUh?=
OPM-2 M3P3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DWb2lEPTB;MUSuOFA5PSEQvF2= NF3pb2pUSU6JRWK=
KARPAS-422 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknqTWM2OD1zND61NVI3KM7:TR?= MnTjV2FPT0WU
RPMI-8226 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zwbWlEPTB;MUSuPFkyPSEQvF2= MoHmV2FPT0WU
KARPAS-45 MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHiTWM2OD1zNT63O|E3KM7:TR?= M4\rZnNCVkeHUh?=
SK-PN-DW NF\PRVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M32xeGlEPTB;MUWuPFY{OSEQvF2= MojaV2FPT0WU
LC-2 NELxe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3NTWM2OD1zNj6xOVA3KM7:TR?= Mmq1V2FPT0WU
NCI-H1648 NIXqd|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjRTWM2OD1zNj6yOVQh|ryP M2XERnNCVkeHUh?=
RL95-2 M4DuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTF4LkO5O|gh|ryP M2Hhc3NCVkeHUh?=
KNS-42 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom4TWM2OD1zNj63Nlc1KM7:TR?= Mo\0V2FPT0WU
RPMI-6666 NU\lS4YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV33OoF4UUN3ME2xOk46OjFzIN88US=> NHPQXJBUSU6JRWK=
SIG-M5 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;0epk6UUN3ME2xO{4yQTB|IN88US=> NGjPbnlUSU6JRWK=
VA-ES-BJ MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DoZmlEPTB;MUeuO|Q2OSEQvF2= NFv2Tm5USU6JRWK=
MONO-MAC-6 M3\kXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfaNpdHUUN3ME2xO{46OzF{IN88US=> NUizVYk4W0GQR1XS
LAN-6 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHexNpFKSzVyPUG4Mlc2PTdizszN NInTU5NUSU6JRWK=
A388 M3Hhdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDaR3dKSzVyPUG5MlMxPTlizszN M{PyeXNCVkeHUh?=
SK-NEP-1 NUTyWVRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\aeFBoUUN3ME2yNE4zOTN{IN88US=> M17yVHNCVkeHUh?=
TE-10 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HqNWlEPTB;MkCuOVIzOSEQvF2= NWS5XnVtW0GQR1XS
HL-60 NInwUZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvrRVBKSzVyPUKwMlkxQTlizszN NWHlfGp1W0GQR1XS
MC116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjl[IxoUUN3ME2yNU44OjJzIN88US=> Mmm1V2FPT0WU
SW962 NXvMbno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n5c2lEPTB;MkGuO|kyPSEQvF2= MmmwV2FPT0WU
NOMO-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ{Lk[1OlQh|ryP MoXrV2FPT0WU
CTB-1 NG\abVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ{Lki2O|Eh|ryP MliwV2FPT0WU
MRK-nu-1 NWPrU3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ{LkmwO|Qh|ryP NEDBRYlUSU6JRWK=
GR-ST NUTV[5pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvXfHhKSzVyPUKzMlc3KM7:TR?= M1v3VnNCVkeHUh?=
HH MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWCwco1VUUN3ME2yOE4xODNizszN MYLTRW5ITVJ?
NCI-H1963 NYn1XmN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ztTWlEPTB;MkSuNFc5OiEQvF2= MWHTRW5ITVJ?
QIMR-WIL M4fZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJ2Lki3O|Ih|ryP MX7TRW5ITVJ?
CGTH-W-1 M1TLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjnVW9KSzVyPUK1MlA4OjNizszN NXjtcG4yW0GQR1XS
LP-1 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHWVodKSzVyPUK1MlY2PTFizszN MWPTRW5ITVJ?
NCI-H748 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF62dmVKSzVyPUK2MlUyOzdizszN MkfBV2FPT0WU
PF-382 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu5RVZKSzVyPUK3MlIzOjNizszN MlTZV2FPT0WU
ATN-1 NYrlSWM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzwRXVbUUN3ME2yO{4{PzN{IN88US=> NXS4PJJJW0GQR1XS
L-540 NY\hfodLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTJ5Lk[0OVkh|ryP MX\TRW5ITVJ?
LXF-289 NYiwe3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G4N2lEPTB;MkeuO|UyQSEQvF2= NILMZpFUSU6JRWK=
LS-513 NHe4UYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ6LkG4NFch|ryP MYnTRW5ITVJ?
NCI-H1581 M3PpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvrTWM2OD1|MD6zPVc3KM7:TR?= NYPNe2xbW0GQR1XS
ES6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjodZBlUUN3ME2zNE43QDl7IN88US=> NVToTGloW0GQR1XS
SW982 NXrjPIZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNyLki1OlYh|ryP MUTTRW5ITVJ?
DOHH-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNzLkW4PVMh|ryP MVrTRW5ITVJ?
DB NXXPNJZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrOTWM2OD1|Mz65OFMyKM7:TR?= MYfTRW5ITVJ?
MPP-89 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDWUZpKSzVyPUO0MlE4PTZizszN MmnKV2FPT0WU
LB831-BLC NEjoWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjKTWM2OD1|ND61NVg1KM7:TR?= MoS3V2FPT0WU
NB5 NH;zdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIixcmtKSzVyPUO0Mlg2OzVizszN NVXnXGZtW0GQR1XS
GB-1 NWrjeFFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfGUVBlUUN3ME2zOU4xPDZ7IN88US=> M2XEPHNCVkeHUh?=
TE-15 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzXdXVKSzVyPUO1MlIzOzhizszN NFTtRotUSU6JRWK=
LC4-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;SSYtnUUN3ME2zOU4{QDR5IN88US=> NF7qOFBUSU6JRWK=
NCI-H747 NHTlPItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN4LkGzOlkh|ryP M3P0cXNCVkeHUh?=
NTERA-S-cl-D1 NX\Md2tRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHqTWM2OD1|OD63N|Q4KM7:TR?= NWXadGd3W0GQR1XS
SK-MM-2 NHP1NJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\SU|hKSzVyPUSwMlEyPDZizszN NUDucWk5W0GQR1XS
TGW NULXSmFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLqTYdPUUN3ME20NU4xPTZ|IN88US=> NFHBUopUSU6JRWK=
ONS-76 NIPtXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTR{LkS4PFMh|ryP NVjLe|VjW0GQR1XS
CPC-N NH\pS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTQb4MyUUN3ME20Nk46QTdzIN88US=> MnjpV2FPT0WU
ES4 NIDvWGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXUTWM2OD12ND60NVU{KM7:TR?= MoXvV2FPT0WU
Daudi NGX3colIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{naS2lEPTB;NEWuNFgzPyEQvF2= NH\rWppUSU6JRWK=
MOLT-4 NVrlNGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTR3LkC4OVMh|ryP MYfTRW5ITVJ?
HT-144 NYPXd3NpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPFdIhRUUN3ME20Ok44OjZizszN MknXV2FPT0WU
SW872 M2jDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITObZlKSzVyPUS4MlE6OzNizszN MV;TRW5ITVJ?
D-283MED MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPGTWM2OD12OD6zOVQzKM7:TR?= Ml;GV2FPT0WU
NCI-H2126 M{frPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHmOJBKSzVyPUS4Mlg1PzZizszN NHT1b5RUSU6JRWK=
NCI-SNU-16 M2j5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjnenBMUUN3ME20PU4zOTR|IN88US=> M1HOT3NCVkeHUh?=
CESS NX6wRlBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR7LkWwPFgh|ryP MYrTRW5ITVJ?
A101D NXvmN2hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTR7Lkm3N|Yh|ryP M1L2NnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pALK / pAKT / pERK / pS6; 

PubMed: 24675041     


H3122 cells were treated with the indicated concentrations of crizotinib or ceritinib for 6 hours. Lysates were probed with antibodies directed against the specified proteins.

pROS1 / ROS1; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

pSTAT3 / STAT3; 

PubMed: 25351743     


Inhibition of phospho-ROS1 by various ALK inhibitors in Ba/F3 models. CD74-ROS1 expressing Ba/F3 cells were exposed to increasing concentrations of crizotinib, ceritinib, AP26113, or ASP3026 for 3 h. Cell lysates were immunoblotted to detect the indicated proteins.

PARP / cleaved caspase-3 / Bax / Bcl-2; 

PubMed: 25193856     


The expression of PARP, cleaved caspase-3, Bax, and Bcl-2 were measured by western blotting after PANC-1 cells were treated with various concentrations of Crizotinib (0-10 μM) for 72 hr.

p-c-Met / c-Met; 

PubMed: 25193856     


Cancer cells with c-MET alterations were exposed to Crizotinib (10 μM) in the indicated times (SNU-5, MKN-45, and SNU-638: gastric cancer cells of c-MET amplification).

p-mTOR; 

PubMed: 26384345     


Immunoblotting for phospho- or total MET, STAT3, AKT, MTOR and ERK in SPC-A1 cells treated with crizotinib for 48 h.

24675041 25351743 25193856 26384345
Immunofluorescence
LC3 / lysosome; 

PubMed: 26384345     


Cells were treated with DMSO or 4 μM crizotinib for 72 h before they were labeled with a fluorescent marker and imaged by fluorescence microscopy. Green: FITC-labeled LC3; Red: lyso-tracker-labeled lysosome; Blue: DAPI-labeled nucleus. 

SRC / Met; 

PubMed: 26517812     


Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in (A) LN-18 and (B) U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

α-tubulin; 

PubMed: 26517812     


LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

cytochrome c; 

PubMed: 25193856     


PANC-1 pancreatic cancer cells were treated with Crizotinib (1 and 10 μM) for 6 hr and stained with anti-cytochrome c antibody, Mitotracker and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification. Cytochrome c (green), mitotracker: red

p-ALK; 

PubMed: 25193856     


PANC-1 cells were also treated with various concentrations (0-10 μM) of Crizotinib and stained with p-ALK antibody and DAPI. The immunostained cells were analyzed under an Olympus confocal laser scanning microscope with 400x magnification.

26384345 26517812 25193856
体内研究

PF-2341066每天按50 mg/kg和75 mg/kg剂量处理GTL-16 模型, 引起大肿瘤 (体积大于600 mm3) 明显衰退,且按43天处理日程处理后,平均肿瘤体积降低60%。在另一项研究中, PF-2341066处理3个月以上,完全抑制GTL-16肿瘤生长,PF-2341066每天按50 mg/kg剂量处理小鼠,3个月后,只有1/12小鼠的肿瘤生长得到提高。PF-2341066每天按50 mg/kg剂量处理NCI-H441 NSCLC 模型处理周期为38天,观察到平均肿瘤体积降低43%。PF-2341066 每天按50 mg/kg剂量作用于 Caki-1 RCC模型,处理周期为33天,观察到平均肿瘤体积降低53%,且每种肿瘤体积降低至少30%。PF-2341066每天按 50 mg/kg剂量作用于 U87MG 恶性胶质瘤或PC-3前列腺癌移植瘤模型,几乎完全抑制肿瘤生长,在实验最后一天,抑制分别达97% 或84%。相反, PF-2341066每天按50 mg/kg剂量口服给药处理 MDA-MB-231 乳腺癌模型,或 DLD-1 结肠癌模型,不会显著抑制肿瘤生长。PF-2341066每天按12.5 mg/kg, 25 mg/kg, 和50 mg/kg剂量作用于 GTL-16 肿瘤,观察到CD31阳性内皮细胞显著降低,这种作用存在剂量依赖性,说明 MVD 受抑制,且具有相关的抗癌高效性,这种作用也存在剂量依赖性。PF-2341066 作用于GTL-16 和 U87MG 模型,显著降低人VEGFA 和IL-8血浆水平,这种作用存在剂量依赖性。PF-2341066口服处理GTL-16 肿瘤,观察到磷酸化的c-Met, Akt, Erk, PLCλ1,和 STAT5水平显著受抑制。[1]PF-2341066 每天按100 mg/kg剂量口服处理携带Karpas299 ALCL 移植瘤的SCID Beige 小鼠,具有抗癌高效性,这种作用存在剂量依赖性,处理15天,所有肿瘤完全衰退。此外, PF-2341066抑制关键NPM-ALK信号调节器, 包括磷脂酶C-γ, 信号转导器,及转录因子3, 细胞外信号调节激酶, 和Akt的激活剂,这些与 NPM-ALK 磷酸化和功能受抑制相关。[2] PF-2341066 抑制骨肉瘤的一些活动行为,及其肿瘤生长(例如, 增殖和存活)和转移 (例如,入侵和形成克隆)。PF-2341066口服饲喂裸鼠,抑制生长和相关的骨肉瘤裸鼠移植瘤的骨基质的形成。[3] PF-2341066 按50 mg/kg 剂量处理 c-MET-扩增的GTL-16移植瘤,引起肿瘤衰退,这与18F-FDG 摄取的缓慢降低相关,且降低葡糖糖转运蛋白 1, GLUT-1的表达。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

生化激酶实验:

使用连续耦合的分光光度测定c-Met催化活性,通过分析NADH消耗率而测定c-Met诱导的ADP产量,这种作用具有时间依赖性。在 340 nm处使用分光光度法在指定时间点测定吸光值的降低而计算NADH的消耗量。为了测定Ki值, 在含实验试剂的实验孔中加入不同浓度PF-2341066,然后在37oC下温育10分钟。加入c-Met酶开始进行实验反应。
细胞实验:

[1]

- 合并
  • Cell lines: GTL-16胃癌细胞和T47D乳腺癌细胞
  • Concentrations: 0 nM-256 nM
  • Incubation Time: 1小时
  • Method:

    GTL-16胃癌细胞和T47D乳腺癌细胞接种在96孔板上,孔中含培养基,培养基中含10% 胎牛血清(FBS),然后转移到无血清培养基中[含0.04%牛血清蛋白(BSA)],处理 24小时。 在调查配体依赖的RTK 磷酸化实验中,加入相应的生长因子,处理20分钟。细胞和 PF-2341066和/或适当配体在指定时间温育1小时,然后使用含 1 mmol/L Na3VO4的HBSS冲洗细胞一次,然后从细胞中获得蛋白裂解物。随后,通过夹心酶联免疫吸附试验法使用特定的捕获抗体在96孔板上测定选定蛋白激酶的磷酸化,使用特点检测抗体测定磷酸化的酪氨酸残基。抗体包被的实验板(a) 在蛋白裂解物存在时,在4oC下过夜;(b)在溶于PBS的1% Tween-20 中冲洗7次;(c)在辣根过氧化物酶标记的抗总磷酸(PY-20)抗体(1:500)中温育20分钟;(d) 再次冲洗7次;(e)在3,3,5,5-四甲基联苯胺过氧化物酶底物中温育,开始显示反应,加入0.09 N H2SO4终止反应; (f)在450 nm 处使用分光光度计测定吸光度。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 携带NCI-H441,或DLD-1,或MDA-MB-231的雌性和雄性nu/nu小鼠
  • Dosages: 12.5 mg/kg/day, 25 mg/kg/day, 和50 mg/kg/day
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 9 mg/mL (19.98 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+dd H2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 450.34
化学式

C21H22Cl2FN5O

CAS号 877399-52-5
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04148066 Recruiting Diagnostic Test: ctDNA blood sample Carcinoma Non-Small-Cell Lung The Netherlands Cancer Institute|Roche Pharma AG July 17 2019 Phase 2
NCT03439215 Recruiting Drug: Lorlatinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale|Clinical Research Technology S.r.l. June 13 2017 Phase 2
NCT02946216 Unknown status Genetic: ctDNA analysis Non-small Cell Lung Cancer Stage III|Non-Small-Cell Lung Cancer Metastatic|Adenocarcinoma of Lung|EGFR Wildtype First People''s Hospital of Hangzhou November 2016 --
NCT02511184 Terminated Drug: Crizotinib|Drug: Pembrolizumab ALK-positive Advanced NSCLC Pfizer|Merck Sharp & Dohme Corp. October 2015 Phase 1
NCT02419287 Unknown status Drug: crizotinib Anaplastic Large Cell Lymphoma ALK-Positive University of Milano Bicocca April 2015 Phase 2
NCT02499614 Unknown status Drug: Crizotinib Carcinoma Non-Small-Cell Lung Fondazione Ricerca Traslazionale December 2014 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you tell me whether this product represents the pure R-form of crizotinib, or is the the racemic Crizotinib, so a mixture of the S- and the R-form?

  • 回答:

    Our S1068 Crizotinib is R enantiomer(except batch 05 and 06, they are racemate), and S7505 is S enantiomer.

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

相关c-Met产品

Tags: 购买Crizotinib (PF-02341066) | Crizotinib (PF-02341066)供应商 | 采购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)价格 | Crizotinib (PF-02341066)生产 | 订购Crizotinib (PF-02341066) | Crizotinib (PF-02341066)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID